Please enter exact key words
A Humanized Anti-RSPO3 Monoclonal Antibody

for Cancer Therapy

Home / Available Projects / A Humanized Anti-RSPO3 Monoclonal Antibody
Drug Name GPCR-targeted Project 003

The RSPO family of four secreted glycoproteins (RSPO 1-4) acts as potent activators of the Wnt/β-catenin signaling pathway, which has been implicated in the development and growth of multiple tumor types, including ovarian, lung and pancreatic cancers. A humanized monoclonal antibody against RSPO3 is under development and showed potential immunostimulation and anti-tumor activity in preclinical studies.

Target R-spondin 3 (RSPO3)
Drug Modality Monoclonal antibody
Indication Cancers
Product Category Biologic
Mechanism of Action RSPO3 antagonists
Status Preclinical
Patent Granted

More Detail Available Upon Request

We look forward to hearing from you.

Our customer service representatives are available 24 hours a day, from Monday to Sunday Online Inquiry

Protheragen's business is growing rapidly after founded in Ronkonkoma, New York. Our business has evolved from the initial intermediary service to encompass segments in equity investment and program incubation.

Protheragen Inc.